Food allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis.

ABSTRACT:

Background

Dupilumab is a monoclonal antibody that inhibits type 2 inflammation through a blockade of interleukin-4 receptor alpha. It is approved for a number of atopic conditions; however, the effect of dupilumab on food allergy has not been fully evaluated.

Objective

To describe the effect of dupilumab use on the clinical course of food allergy in patients receiving dupilumab for comorbid atopic dermatitis.

Methods

This retrospective study reviewed electronic medical records of children with food allergy at a single, tertiary care center receiving dupilumab for the treatment of atopic dermatitis. Food allergy testing, including skin prick test (SPT) and specific IgE (sIgE), and the outcomes of oral food challenges undertaken during routine clinical care were review

SUBMITTER: Emerson AG 

PROVIDER: S-EPMC12609014 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature